secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001104659-22-059902
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage raises $5.1M in private placement to advance esophageal implant clinical trial
--------------------------------------------------------------------------------

- Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.
- Warrants exercisable at $8.88/share for 5 years; $4.8M received, $260K expected shortly.
- Proceeds to accelerate FDA-approved 10-patient Phase 1/2 trial of Biostage Esophageal Implant for severe esophageal disease.
- Company also developing Biostage Bronchial Implant for lung cancer and birth defects.
- CEO David Green expressed optimism about advancing pipeline for patients and shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922059902/0001104659-22-059902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922059902/tm2215472d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-059902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer